Dexcom launched its first over-the-counter continuous glucose monitor called Stelo on Monday. Users can buy a one-month ...
The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription, which can be used by diabetics on oral medications, as well as non ...
DexCom (NASDAQ:DXCM), known for its continuous glucose monitoring (CGM) systems, recently unveiled its Q4 2024 earnings report on Feb. 13, 2025. This release highlighted an 8% growth in revenue ...
After-hours stock movements include GameStop (GME), Twilio (TWLO), and DexCom (DXCM). To watch more expert insights and analysis on the latest market action, check out more Asking for a Trend  ...
Dexcom (DXCM) stock is down over 40% in Friday's session after the continuous glucose monitoring technology company fell short of revenue estimates for its second quarter and slashed its full-year ...
DexCom Q4 revenue rose 8% YoY to $1.11 billion, beating estimates of $1.104 billion. DexCom reaffirms 2025 revenue guidance at $4.60 billion vs. consensus of $4.61 billion. Get real-time earnings ...
Dexcom (DXCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 13. Analyst Mike Kratky from Leerink Partners maintained a Buy rating on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback